Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 7/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22944329 | 0.82 | TNK2 (0.49) | BTKTNK2USP30 | |
| SCHEMBL28672765 | 0.78 | BTK (0.40) | BTKTNK2 | |
| SCHEMBL19203205 | 0.78 | BTK (0.56) | BTKUSP30 | |
| SCHEMBL19203182 | 0.77 | BTK (0.50) | BTKTNK2ACACB | |
| SCHEMBL21425203 | 0.77 | MAPK1 (0.41) | BTKTNK2UCHL1USP30 | |
| SCHEMBL22944325 | 0.76 | MAPK1 (0.44) | USP30 | |
| SCHEMBL22944628 | 0.73 | NAMPT (0.48) | UCHL1USP30 | |
| SCHEMBL6352947 | 0.73 | MAPK1 (0.49) | UCHL1USP30 | |
| SCHEMBL29987356 | 0.72 | BTK (0.49) | BTKTNK2 | |
| SCHEMBL19203181 | 0.72 | BTK (0.70) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602818-B | Pyrazole fused ring derivatives, preparation method thereof and application thereof in treating cancer, inflammation and immune diseases | 北京诺诚健华医药科技有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3409672-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017128917-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 北京诺诚健华医药科技有限公司 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BTK, SYK, JAK1 | BTK 1/4885TNK2 328/4885ACACB 3969/4885 |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BTK, SYK, JAK1 | BTK 1/4885TNK2 328/4885ACACB 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.